Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Solid Tumors Harboring NTRK Fusion 1Recurrence 1Liver Neoplasms 1Insulin-Like Growth Factor I, Resistance To 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Breast Neoplasms, Male 1Breast Neoplasms 1Advanced Solid Tumor 1

Interventions

Sorafenib 22Bevacizumab 15pembrolizumab 10durvalumab 7Nivolumab 7Ipilimumab 6Drug Therapy 6atezolizumab 5Talaporfin 5spartalizumab 4regorafenib 4lenvatinib 4derazantinib 3Ramucirumab 3Photochemotherapy 3Leucovorin 3Injections 3Fluorouracil 3Doxorubicin 3tremelimumab 2toripalimab 2seocalcitol 2relatlimab 2phosphomannopentaose sulfate 2liposomal doxorubicin 2exatecan 2cabozantinib 2brivanib 2Phototherapy 2Oxaliplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Liver Neoplasms × Receptor Protein-Tyrosine Kinases × Clear all
NCT00956436 2013-09-16

Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC)

Biogen

Phase 1 Completed
40 enrolled
Gastrointestinal

Insulin-Like Growth Factor I, Resistance To, Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡